Clinical Trials
12
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
2
16.7%
Completed
10
83.3%
No approval data available
- The Dubai LITTLE FALCON program deployed citywide rapid whole-genome sequencing (rWGS) across NICUs and PICUs, enrolling 100 critically ill pediatric patients from 18 countries with a median turnaround of 3.4 days. - rWGS achieved a 53% diagnostic yield (95% CI 43.3–62.5%), significantly outperforming standard-of-care testing (30%) and driving clinical management changes in 53% of patients. - Diagnostic yield reached 80% among children of consanguineous parents, reflecting the high burden of autosomal recessive disease in this Middle Eastern and Asian population. - The program signals rWGS's transition from investigational tool to standard-of-care infrastructure, raising unresolved regulatory questions about AI-driven variant interpretation under FDA clinical decision support guidance.
- Whole-genome newborn screening studies such as GUARDIAN, BabyScreen+, and BabyDetect are identifying serious genetic conditions that conventional screening would miss in roughly 1.6% to 4% of infants. - Preliminary GUARDIAN data from 15,000 newborns confirmed genetic conditions in 2.7% of participants, with more than 90% of detected diseases missed by traditional testing methods. - Early diagnosis has enabled life-saving interventions, including a bone-marrow transplant in a six-month-old with familial HLH and pre-symptomatic treatment for a six-month-old with Batten disease. - Researchers caution that genotype–phenotype uncertainty, gene-list selection, and clear communication of results remain key challenges before broad implementation.
- The global epigenomics market is projected to grow from US$16.9 billion in 2024 to US$69.6 billion by 2034, a 15.2% CAGR. - Oncology dominates applications with a 57.2% share, while DNA methylation leads the technology segment at 48.1% of revenue. - More than 10 epigenetic drugs are approved and over 35 epigenetic therapies are in clinical trials worldwide, signaling expanding therapeutic investment. - North America holds a leading 41.3% market share, with Asia-Pacific forecast to record the fastest growth through 2034.
- Illumina has launched TruPath Genome, a whole-genome sequencing workflow that eliminates traditional library prep and delivers 16 genomes per day in about 10 minutes of hands-on time. - The platform fully phases up to 98% of genes and extends accurate variant calling into difficult-to-map 'dark regions' of the genome using on-flow-cell library preparation and DRAGEN algorithms. - Data presented at AGBT showed TruPath Genome resolving challenging loci including the SMN1/SMN2 region in spinal muscular atrophy and genes linked to inherited adrenal disorders. - Broad Clinical Labs is among the first adopters, while more than 30 early access customers including GeneDx, Rady Children's Hospital and Baylor College of Medicine piloted the technology over 16 months.
- Illumina announced the addition of three new member companies to its Billion Cell Atlas alliance, including AI-native drug developer Formation Bio, on July 16, 2026. - The Atlas has sequenced over 350 million cells to date, generating more than six petabytes of genomic data across hundreds of disease-relevant and healthy cell types. - Formation Bio plans to leverage the Atlas's genome-wide CRISPR perturbation data to credential target-indication pairs and improve asset-selection decisions for first-in-class medicines. - The program, launched in January 2026 with founding members AstraZeneca, Merck, and Eli Lilly, aims to train virtual cell models and accelerate the journey from biological insights to approved drugs.
- Illumina reported Q1 revenues of $1.09 billion, up 4.8% year-on-year, beating analyst expectations and raising full-year EPS guidance. - Bruker delivered $823.4 million in revenue, a 2.7% increase, surpassing analyst estimates across revenue, EPS, and organic growth metrics. - 10x Genomics posted $150.8 million in revenue, a 2.6% year-on-year decline, representing the slowest revenue growth among its peer group. - Azenta was the weakest performer with flat revenues of $144.8 million, missing both revenue and EPS analyst estimates.
- Precision medicine market valued at USD 118.69 billion in 2025 is projected to reach USD 544.26 billion by 2035, growing at a CAGR of 16.45%. - AI-enabled real-world data from EHRs, claims, and wearables is overcoming traditional clinical trial limitations by capturing diverse patient experiences over time. - Integration of genomic data with RWD is enabling molecular profiling and targeted therapies, particularly in oncology for breast, lung, and colorectal cancers. - Key barriers remain including data representation gaps, privacy concerns, and the need for strong governance and clinical validation to ensure equitable precision care.
- Daniel M. Skovronsky, MD, PhD, Chief Scientific and Product Officer of Eli Lilly and President of Lilly Research Laboratories, has been appointed to Illumina's Board of Directors effective June 16, 2026. - Dr. Skovronsky brings extensive experience in drug discovery, clinical development, and translational medicine to Illumina's work advancing genomics and multiomics platforms. - Illumina CEO Jacob Thaysen highlighted that Skovronsky's leadership in building large research portfolios will strengthen the company's innovation across genomics, multiomics, and precision medicine. - Skovronsky previously founded Avid Radiopharmaceuticals, served on Myriad Genetics' board, and holds both an MD and PhD from the University of Pennsylvania.
- The global single-cell multiomics market, valued at USD 2.99 billion in 2025, is projected to reach USD 18.20 billion by 2035 at a CAGR of 19.81%, according to SNS Insider. - Oncology dominated the application segment with a 38.90% revenue share in 2025, while single-cell proteomics is expected to grow at the fastest CAGR of 23.16% through 2035. - Droplet-based microfluidics accounted for 56.30% of market revenue in 2025, though spatial-omics platforms are forecast to achieve the highest CAGR of 24.50%. - North America led regional markets with 41.85% of total revenue, while Asia Pacific is anticipated to register the strongest growth over the forecast period.
- At the European Society of Human Genetics 2026 conference in Gothenburg, Sweden, more than 6,000 global leaders gathered to discuss advances in genomic medicine. - Professor Emma Baple, medical lead for the NHS England Rapid Genome Sequencing Service for Critically Unwell Children, highlighted the clinical benefits of whole-genome sequencing. - The meeting emphasized the rapid progress in sequencing technologies and the growing integration of genomic insights into routine clinical practice. - Speakers shared real-world experiences implementing genomics at scale, underscoring how genomic medicine could evolve to improve outcomes for critically ill patients.
